

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/644,052		ATTY. DOCKET NO.: C1037.70048US00	
				FILING DATE: August 19, 2003		CONFIRMATION NO.: 4791	
				APPLICANT: Arthur M. Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	1	of	2				

#### U.S. PATENT DOCUMENTS

Examiner's Initials <sup>4</sup>	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		7,605,138	B2	Krieg	10-20-2009
		7,615,539	B2	Krieg et al.	11-10-2009
		7,674,777	B2	Krieg	03-09-2010
		7,713,529	B2	Krieg et al.	05-11-2010
		7,723,022	B2	Krieg et al.	05-25-2010
		7,723,500	B2	Krieg et al.	05-25-2010
		7,776,344	B2	Hartmann et al.	08-17-2010
		7,795,235	B2	Krieg et al.	09-14-2010
		7,807,803	B2	Krieg et al.	10-05-2010
		7,820,379	B2	Bauer et al.	10-26-2010
		7,879,810	B2	Krieg et al.	02-01-2011
		7,888,327	B2	Krieg et al.	02-15-2011
		2009-0117132	A1	Readett et al.	05-07-2009
		2009-0214578	A1	Bauer	08-27-2009
		2009-0306177	A1	Uhlmann et al.	12-10-2009
		2009-0311277	A1	Krieg	12-17-2009
		2010-0166780	A1	Debelak et al.	07-01-2010
		2010-0183639	A1	Uhlmann et al.	07-22-2010
		2010-0285041	A1	Uhlmann et al.	11-11-2010
		2011-0033421	A1	Hartmann et al.	02-10-2011

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials <sup>4</sup>	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
		WO	01/93905	A1	Cistem Biotechnologies GMBH	12-13-2001	

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials <sup>4</sup>	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		AGRAWAL, Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta. 1999 Dec 10;1489(1):53-68. Review.	
		HARTMANN et al., CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Ther. 1999 May;6(5):893-903.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

<sup>4</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/644,052		ATTY. DOCKET NO.: C1037.70048US00	
				FILING DATE: August 19, 2003		CONFIRMATION NO.: 4791	
				APPLICANT: Arthur M. Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	2	of	2				

		KAISHO et al., Toll-like receptors as adjuvant receptors. <i>Biochim Biophys Acta</i> . 2002 Feb 13;1589(1):1-13. Review.	
		KRIEG et al., Identification of an oligodeoxynucleotide sequence motif that specifically inhibits phosphorylation by protein tyrosine kinases. <i>Antisense Nucleic Acid Drug Dev.</i> 1997 Apr;7(2):115-23.	
		UHL MANN et al., Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression. <i>Methods Enzymol.</i> 2000;313:268-84.	
		UHL MANN, Oligonucleotide technologies: synthesis, production, regulations and applications. 29-30th November 2000, Hamburg, Germany. <i>Expert Opin Biol Ther.</i> 2001 Mar;1(2):319-28.	
		VOLLMER, Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9. <i>Expert Opin Biol Ther.</i> 2005 May;5(5):673-82. Review.	
		WAHLESTEDT et al., Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. <i>Proc Natl Acad Sci U S A.</i> 2000 May 9;97(10):5633-8.	
		WEINER et al., The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. <i>J Leukoc Biol.</i> 2000 Oct;68(4):455-63.	

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR § 1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR § 1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR § 1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. § 120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

<sup>8</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.